Comparison of two lung cancer screening scores among patients with chronic obstructive pulmonary disease: A community study.


Journal

The clinical respiratory journal
ISSN: 1752-699X
Titre abrégé: Clin Respir J
Pays: England
ID NLM: 101315570

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 18 05 2018
revised: 16 10 2018
accepted: 24 12 2018
pubmed: 1 1 2019
medline: 20 8 2019
entrez: 1 1 2019
Statut: ppublish

Résumé

Based on the National Lung Cancer Screening Trial (NLST), guidelines on screening programs for lung cancer have recommended low-dose computed tomography (LDCT). De Torres et al made a score for COPD patients (COPD-LUCSS) to improve their selection criteria. To examine and compare the discriminating value of both scores in a community-based cohort of COPD patients. Four hundred and twenty-two ever-smokers with COPD from the GenKOLS study in Bergen were merged with the Cancer Registry of Norway. We divided the patients into groups of high and low risk according to the COPD-LUCSS and the NLST criteria. Cox regression and logistic regression were used to analyse the associations between the scores and lung cancer. We used Harrell's C and area under the curve (AUC) to estimate discriminating values and to compare the models. Hazard ratio for the high risk vs the low risk in the COPD-LUCSS was 3.0 (1.4-6.5 95% CI), P < 0.01. Hazard ratio for the NLST criteria was 2.2 (95% CI 1.1-4.5), P < 0.05. Harrell's C was 0.63 for the COPD-LUCSS and 0.59 for the NLST selection criteria. AUC was 0.61 for COPD-LUCSS and 0.59 for NLST criteria. Comparing tests showed no differences (P = 0.76). Although the COPD-LUCSS and the NLST criteria were associated with increased risk of lung cancer, the AUC and Harrell's C values showed that these models have poor discriminating abilities in our cohort of COPD patients. The COPD-LUCSS was not significantly better than the NLST criteria.

Identifiants

pubmed: 30597746
doi: 10.1111/crj.12988
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Pagination

114-119

Subventions

Organisme : GlaxoSmithKline Research & Development Limited

Informations de copyright

© 2018 John Wiley & Sons Ltd.

Auteurs

Ane Aamli Gagnat (AA)

Department of Clinical Science, University of Bergen, Bergen, Norway.

Amund Gulsvik (A)

Department of Clinical Science, University of Bergen, Bergen, Norway.

Per Bakke (P)

Department of Clinical Science, University of Bergen, Bergen, Norway.

Miriam Gjerdevik (M)

Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH